[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"methamphetamine-induced-psychosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:methamphetamine-induced-psychosis":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,72,90,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100628256","psychiatric-symptom-characteristics-in-methamphetamine-induced-psychosis-with-and-without-lifetime-cannabis-use-100628256",false,"NCT07459270","Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use","Investigation of Factors Associated With Psychiatric Symptoms in Participants Diagnosed With Methamphetamine-Induced Psychotic Disorder With and Without Lifetime Cannabis Use","1. For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n   * Diagnosis of Cannabis Use Disorder according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n\n   • Rheumatoid arthritis\n\n   • Systemic lupus erythematosus\n\n   • Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n\n   • Medication-free for at least one month prior to admission\n\n   • Age ≥ 18 years and \\\u003C65 years\n\n   • Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder",true,"MALE","18 Years","65 Years",{"count":21,"type":22},90,"ESTIMATED","OBSERVATIONAL","This prospective cohort study aims to investigate factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU). Participants hospitalized at Elazığ Mental Health and Diseases Hospital who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MP will be included.\n\nParticipants will be divided into two groups based on the presence or absence of LCU. Psychiatric symptoms and clinical characteristics will be assessed weekly during an eight-week inpatient follow-up period using standardized psychometric instruments.\n\nThe study aims to determine whether LCU influences the course and severity of psychiatric symptoms in MP and to identify environmental, individual, and familial factors associated with symptom progression.",[26,27],"Methamphetamine Induced Psychosis","Cannabis Use",[29,30,31,32,33,34,35],"Methamphetamine","Cannabis","Marijuana","Psychiatric Symptoms","Longitudinal Study","Methamphetamine-Induced Psychotic Disorder","Lifetime Cannabis Use","NOT_YET_RECRUITING","2026-03-04",{"date":39,"type":40},"2026-03-09","ACTUAL",{"date":42,"type":22},"2026-03-16",{"date":44,"type":22},"2026-11-23",{"name":46,"class":47},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100628254","ecg-findings-in-methamphetamine-use-100628254","NCT07459244","ECG Findings in Methamphetamine Use","Electrocardiogram Findings in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Prospective Observational Cohort Study","1. For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MUD according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MUD\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MP according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Exclusion Criteria:\n   * Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n3. For Healthy Control Group:\n\n   \\*Inclusion Criteria:\n   * No psychiatric diagnosis\n   * No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Healthy Control Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than schizophrenia\n   * Alcohol\u002Fdrug\u002Fsubstance use",{"count":57,"type":22},240,"This prospective cohort study aims to examine and compare electrocardiogram (ECG) parameters in subjects diagnosed with Methamphetamine Use Disorder (MUD) and Methamphetamine-Induced Psychotic Disorder (MP) during inpatient psychiatric treatment. ECG findings at hospital admission and during remission prior to discharge will be evaluated and compared between groups. The study also aims to determine whether methamphetamine-induced psychosis is associated with greater ECG abnormalities and increased cardiac risk compared to methamphetamine use without psychosis.",[60,26],"Methamphetamine Use Disorder",[29,60,62,63,64],"Methamphetamine-Induced Psychosis","Electrocardiography","Cardiac Risk","RECRUITING",{"date":39,"type":40},{"date":68,"type":40},"2025-04-07",{"date":70,"type":22},"2026-05-11",{"name":46,"class":47},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":48},"100628255","psychiatric-symptom-predictors-in-methamphetamine-induced-psychosis-100628255","NCT07459257","Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis","Investigation of Factors Associated With Psychiatric Symptoms in Methamphetamine-Induced Psychotic Disorder: One-Year Longitudinal Study","* Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n  \\*Inclusion Criteria:\n  * Diagnosis of MP according to DSM-5-TR\n  * Medication-free for at least one month prior to admission\n  * Age ≥ 18 years and \\\u003C65 years\n  * Provided informed consent\n* Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n  * Exclusion Criteria:\n\n    * Hypertension\n    * Diabetes mellitus\n    * Chronic kidney disease\n    * Rheumatoid arthritis\n    * Systemic lupus erythematosus\n    * Cardiac illness\n    * Severe neurological disorders\n    * Immunological or systemic illness\n    * Primary psychiatric disorders other than MP\n    * Alcohol use disorder",{"count":80,"type":22},150,"This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed\u002Fwill be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed\u002Fwill be assessed monthly using standardized psychometric instruments.\n\nThe study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.",[26],[29,62,32,34,33],{"date":39,"type":40},{"date":86,"type":40},"2025-02-03",{"date":88,"type":22},"2026-08-17",{"name":46,"class":47},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":48},"100627545","lrfn5-and-olfm4-in-methamphetamine-induced-psychosis-100627545","NCT07450027","LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis","Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study","49 Years",{"count":98,"type":22},120,"This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.",[60,101],"Methamphetamine-induced Psychosis",[103,104,29,105,106,107],"LRFN5","OLFM4","Psychotic Disorder","Methamphetamine Psychosis","Psychostimulants","2026-02-27",{"date":37,"type":40},{"date":111,"type":40},"2025-09-01",{"date":113,"type":22},"2026-04-01",{"name":46,"class":47},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":122,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":126,"studyType":23,"phases":4,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100607142","this-hospital-based-observational-study-employed-a-study-will-be-conducted-in-sohag-university-hospital-clinics-aiming-to-ensure-cases-presented-with-psychosis-in-two-phases-to-differentiate-into-two-groups-a-case-of-schizophrenia-or-a-case-of-methamphetamine-induced-psychosis-100607142","NCT07184710","This Hospital-based Observational Study Employed a Study Will be Conducted in Sohag University Hospital Clinics Aiming to Ensure Cases Presented With Psychosis in Two Phases to Differentiate Into Two Groups a Case of Schizophrenia or a Case of Methamphetamine Induced Psychosis.","Comparative Study Between Methamphetamine Induced Psychosis and Schizophrenia in Sohag Governorate","Inclusion Criteria:\n\n* Consecutive patients presenting to the outpatient department with active psychotic symptoms were screened for inclusion. Eligible participants were adults (age ≥18 ≤60) meeting DSM-5 criteria for either methamphetamine-induced psychotic disorder or schizophrenia.\n\nExclusion Criteria:\n\n* included presence of primary neurological disorders (e.g., epilepsy, dementia), significant medical illness affecting cognition, or inability to participate in interviews.","ALL","60 Years",{"count":125,"type":22},200,"3 Months","This hospital-based observational study employed prospective follow up study will be conducted in sohag university hospital clinics aiming to ensure cases presented with psychosis in two phases to differentiate into 2 groups (a case of schizophrenia or a case of METH induced psychosis)\n\nPhases-1 includes:\n\n1. Screening and Consent: All consecutive patients meeting initial criteria for psychosis were informed about the study. After explaining the procedures, written informed consent was obtained.\n2. Diagnostic Interview: Each participant underwent a SCID-5 interview to confirm DSM-5 diagnoses. The SCID modules relevant to psychotic disorders were used (including the psychotic and substance-use modules). Information from patient self-report and available medical records was incorporated into the diagnostic assessment.\n3. Symptom Rating: Following diagnosis, a trained clinician conducted the PANSS interview. This involved structured questions about symptoms over the past week, supplemented by clinical observation. Each PANSS item was scored on a 1-7 scale according to established guidelines. The positive- and negative-symptom subscale scores were recorded for analysis.\n4. Clinical Data: A semi-structured form was used to record demographic data, psychiatric history (age at onset, duration of illness), medication history, and details of methamphetamine use (duration, frequency, last use and drug screening). Data were entered into a secure study database.\n\nPhase 2 includes:\n\nFollow up visit after 3 months to obtain :\n\nPositive and Negative Syndrome Scale (PANSS) Drug screening Time of recovery, response to treatment, relapse , job dysfunction duration.\n\nAim of the study:\n\nThe study aims to compare between:\n\n1. Clinical profile-risk factors-of schizophrenia vs methamphetamine induced psychosis in sohag governorate\n2. Compare between response to treatment\n\n   * the need of hospitalization and its duration\n   * time of recovery\n   * job dysfunction duration",[129,130,26],"Comparing Clinical Profile and Prognosis of Schizophrenia Versus Methamphetamine Induced Psychosis","SCHIZOPHRENIA",[132,133,134,135],"psychosis","schizophrenia","METH","comparative","2025-09-26",{"date":138,"type":40},"2025-10-02",{"date":140,"type":22},"2025-10-24",{"date":142,"type":22},"2026-08-25",{"name":144,"class":145},"Sohag University","OTHER"]